Cycle on Aug 31, 2026

I will start by listing the current open threads and watches for this topic to see what has been prioritized, what needs to be followed up on, and if any existing watches have fired.

I will now retrieve the existing notes to see what findings are already recorded and what their slugs are, so that I can update them or create new ones appropriately.

Let's see what's happening recently in the GLP-1 space. The date is August 31, 2026. Let's do some web searches to see if there are any major pipeline updates, earnings reports, clinical readouts, or regulatory updates for the core companies (Novo Nordisk, Eli Lilly, Amgen, Viking Therapeutics, Structure Therapeutics) or other relevant players (like Kailera, Pfizer, Metsera, Roche, etc.) or broader market developments since mid-August 2026. Let's start with a broad search on GLP-1 updates from August 2026.

Excellent. Let's see if we can find more details. Let's fetch the BioSpace article: `https://www.biospace.com/drug-development/myriad-catalysts-on-deck-for-obesitys-brightest-stars-as-market-continues-to-accelerate` or `https://www.biospace.com/business/novo-takes-first-round-of-oral-obesity-duel-can-it-stay-ahead-of-lilly` to get the latest analysis. Let's do a search first to get the URL of "novo takes first round of oral obesity duel" or fetch the BioSpace article about "myriad catalysts on deck". Let's fetch the first URL: `https://www.biospace.com/drug-development/myriad-catalysts-on-deck-for-obesitys-brightest-stars-as-market-continues-to-accelerate`.

This is extremely informative. Let's analyze what's happening. Let's first check if there are any other recent news articles about Viking Therapeutics, Structure Therapeutics, Amgen, Eli Lilly, and Novo Nordisk. Let's search for Viking Therapeutics VK2735 Phase 1 maintenance study results or updates in August 2026. Wait! One of the open threads is: "Viking Therapeutics is expected to release data from its exploratory Phase 1 maintenance study of VK2735 in Q3 2026. This study evaluates transitioning patients from weekly SC injections to biweekly or monthly SC dosing, or daily/weekly oral dosing. A successful trial would demonstrate the clinical viability of flexible long-term maintenance dosing, a major competitive differentiator." The date is August 31, 2026. Let's see if Viking Therapeutics has released this data yet. Let's search for `Viking Therapeutics VK2735 maintenance study Q3 2026` or `VK2735 maintenance data`.

Okay, so the maintenance dosing study for Viking Therapeutics (VK2735) has not read out yet, but it is highly anticipated for Q3 2026. The stock is seeing significant movement and interest. Let's do some more searches to see if there are any other major developments. Wait, let's look at Eli Lilly and Novo Nordisk. Let's do a search on Novo Nordisk's latest earnings or pipeline updates or any other major events in August 2026. Wait, let's check: 1. `Novo Nordisk v. Eli Lilly Preliminary Injunction Ruling on GLP-1 Ads` 2. `Amgen MariTide Type 2 Diabetes Phase 3 Trial Initiations` 3. `Structure Therapeutics Aleniglipron Body Composition and SWITCH Trial Readouts` 4. `Eli Lilly Retatrutide Regulatory Submission` 5. `Novo Nordisk Wegovy and Ozempic $675 List Price Cut Implementation` 6. `Kailera v. Structure Section 1782 Discovery Ruling` 7. `Viking Therapeutics VK3019 Phase 1 SAD Obesity Trial Readout` 8. `Viking Therapeutics Oral VK2735 Phase 3 Trial Initiation` 9. `Eli Lilly Foundayo (Orforglipron) Europe and UK Commercial Launch` 10. `Amgen 2010–2015 IRS Tax Court Ruling` 11. `Viking Therapeutics Q3 2026 VK2735 Phase 1 Maintenance Study Readout` Let's check if there are any updates on `Kailera v. Structure` or `Kailera Section 1782`. Let's search `Kailera Structure Therapeutics Section 1782`. This is a very specific legal dispute. Let's search for it.

Let's search for `Kailera Structure Therapeutics` or `Kailera "1782"` or `Section 1782` in general to see if there is any court filing or update in the Northern District of California. Let's do a search on `Kailera Structure` or `"Section 1782" Structure`.

Ah! Look at this: `ORDER by Judge Thomas S. Hixson. San Francisco` on `7/23/2026` or around that date. Let's see what the order is. Let's search for `Kailera Therapeutics Thomas S. Hixson 1782 order` or `Kailera Therapeutics v. Structure Therapeutics Order`. Let's search on Google or PACER dockets to see what happened with this order. Let's run a web search.

Let's search for the actual docket of `3:2026mc80216` or `26-mc-80216` to see what orders have been issued in August 2026. Let's do a search.

Let's search for `Kailera Therapeutics, Inc. v. Structure Therapeutics, Inc. docket courtlistener` or `justia`.

Let's fetch `https://dockets.justia.com/docket/california/candce/3:2026mc80216/474787` to see if there is any update or if we can see the docket list.

Ah, the docket retrieved on July 31, 2026, doesn't show a final ruling on the ex parte application yet, only pro hac vice motions. Let's do a quick search to see if any ruling has been made on the ex parte application in August 2026. Let's search for `Kailera "1782" order "Thomas S. Hixson" OR "Hixson" August 2026`.

No results. Let's widen the search to `Kailera "1782" August 2026` or just `Kailera Structure Therapeutics`. Let's search for `Kailera Structure Therapeutics` in the last month.

Let's fetch the 247wallst article on Kailera: `https://247wallst.com/investing/2026/08/18/kailera-therapeutics-the-record-breaking-obesity-ipo-big-pharma-cannot-ignore/` to see what details it has about Kailera's pipeline and current status. Let's fetch it.

Okay, let's look at public-markets data for these companies. We have `market_view` available for `NVO`, `LLY`, `AMGN`, `VKTX`, `GPCR` (Structure Therapeutics), and `KLRA` (Kailera Therapeutics). Let's call `market_view` for each of them to get their current financial positions, latest multi-quarter revenue/earnings trajectories, valuation multiples, and recent price movements. Let's do this sequentially or in parallel. Let's start with `NVO` (Novo Nordisk).

This is a great snapshot. Let's look at Eli Lilly (LLY) next. Let's call `market_view` for `LLY`.

Wow, Eli Lilly is growing rapidly. Trailing twelve month revenue is $79.67B, up 47.7% YoY. Operating margin is 54.2%. Profit margin 33.5%. Q2 revenue was $22.97B, op income $8.98B, net income $7.09B. Novo Nordisk, on the other hand, is trading at a low P/E of 11.29. Wait! Is that right? TTM revenue is $329.43B, net income is $20.99B (Q2) and $48.56B (Q1). Wait, let's look at NVO's market cap: $201.64B. That's extremely low compared to LLY's $1.05T. Let's pull `market_view` for `AMGN` (Amgen).

Great. Now let's call `market_view` for `VKTX` (Viking Therapeutics). This is a highly relevant smaller biotech. Let's call `market_view`.

Fascinating. Let's call `market_view` for `GPCR` (Structure Therapeutics). Let's do that.

Excellent. Let's call `market_view` for `KLRA` (Kailera Therapeutics). Let's see if it's composed.

Excellent. Now we have market views for all the key companies: Novo Nordisk (NVO), Eli Lilly (LLY), Amgen (AMGN), Viking Therapeutics (VKTX), Structure Therapeutics (GPCR), and Kailera Therapeutics (KLRA). Let's carefully examine the news and events. Wait, let's write or update our notes. What notes do we have? 1. `eli-lilly-foundayo-orforglipron-fda-approval` - "Eli Lilly's Foundayo and Novo Nordisk's Wegovy Pill Clash in Oral GLP-1 Showdown" Let's see: Lilly's oral orforglipron was approved under the name **Foundayo**? Yes, the BioSpace article mentions: "Current market leader Eli Lilly is setting records with its injectable GLP-1 tirzepatide products Mounjaro and Zepbound and continues to propel its commercial engine with the recently approved oral newcomer Foundayo. Many of Lilly’s achievements in obesity have come in the form of growing the prescription base, with the U.S. launch of Foundayo in particular benefiting from a massive push to bring new patients into the fold." Let's check when Foundayo was approved and how the oral market is clashing. Wait, let's search for `Eli Lilly Foundayo` or `Lilly Foundayo` to get the exact details of its approval and launch. Let's do a web search.

Ah! The search budget is spent. That is fine, I have a massive wealth of information right now. Let's process everything we have. Let's review the active threads and see if any of them can be resolved or updated. Wait, let's look at the threads: 1. `Novo Nordisk v. Eli Lilly Preliminary Injunction Ruling on GLP-1 Ads` (fire_date: 2026-12-31) - Ongoing/future, no ruling yet. 2. `Amgen MariTide Type 2 Diabetes Phase 3 Trial Initiations` (fire_date: 2026-12-31) - Future. 3. `Structure Therapeutics Aleniglipron Body Composition and SWITCH Trial Readouts` (fire_date: 2026-12-31) - Future (Q4 2026). 4. `Eli Lilly Retatrutide Regulatory Submission in Obesity and Comorbidities` (fire_date: 2027-03-31) - Future (Q1 2027). 5. `Novo Nordisk Wegovy and Ozempic $675 List Price Cut Implementation` (fire_date: 2027-01-01) - Future. 6. `Kailera v. Structure Section 1782 Discovery Ruling` (fire_date: 2026-12-31) - Let's see: the docket shows pro hac vice motions but no final ruling on the ex parte application yet. So this is still pending. 7. `Viking Therapeutics VK3019 Phase 1 SAD Obesity Trial Readout` (fire_date: 2027-06-30) - Future. 8. `Viking Therapeutics Oral VK2735 Phase 3 Trial Initiation` (fire_date: 2026-12-31) - Future (Q4 2026 or H2 2026). 9. `Eli Lilly Foundayo (Orforglipron) Europe and UK Commercial Launch` (fire_date: 2027-03-31) - Future. 10. `Amgen 2010–2015 IRS Tax Court Ruling` (fire_date: 2026-12-31) - Future. 11. `Viking Therapeutics Q3 2026 VK2735 Phase 1 Maintenance Study Readout` (fire_date: 2026-09-30) - This is expected in Q3 2026 (which ends in September). It has not been published yet. Wait, are there any threads that we can resolve? No, these are all future-looking watches. But we can write highly informative findings based on the latest data we have. Let's see what notes we should write or update. We have: 1. `eli-lilly-foundayo-orforglipron-fda-approval` - "Eli Lilly's Foundayo and Novo Nordisk's Wegovy Pill Clash in Oral GLP-1 Showdown" Let's update this note! Wait, let's look at what the original note covers: "The competitive battle in the once-daily oral GLP-1 receptor agonist market has entered a new phase of clinical differentiation and commercial scaling. In the second quarter of 2026, Novo Nordisk's..." We have a ton of new details: - Foundayo (orforglipron) was approved on April 1, 2026, under the FDA Commissioner's National Priority Voucher (CNPV) pilot program (the fastest approval of a new molecular entity since 2002, taking only 50 days, nearly 10 months ahead of its original January 20, 2027 PDUFA date). - Foundayo has a major competitive advantage: it's a once-daily small-molecule (non-peptide) oral GLP-1 that can be taken at any time of day with *no food or water restrictions*, unlike Novo's Wegovy pill (which has strict fasting requirements). - Lilly launched Foundayo via LillyDirect starting at $25/month with commercial coverage and $149/month for self-pay. Medicare Part D patients can access it for $50/month under the Medicare GLP-1 Bridge program. - However, Novo Nordisk still holds a strong position in the oral market, claiming about 90% of weekly prescriptions with its Wegovy pill as of July 2026 (approx. 1.5 million people taking it), though Novo suffered a revenue stumble for the Wegovy pill in Q2 2026. - Let's fetch the market views for NVO and LLY. - LLY TTM Revenue: $79.67B (+47.7% YoY) | Gross margin: 83.4% | Latest Q EPS: $8.38 | Market Cap: $1.05T. - NVO TTM Revenue: $329.43B (+2.1% YoY) | Gross margin: 82.0% | Latest Q EPS: $0.96 | Market Cap: $201.64B. Wait, let's compare these and write a stellar update for `eli-lilly-foundayo-orforglipron-fda-approval`. Let's write the note. Wait, let's also look at Viking Therapeutics. We have: `viking-therapeutics-oral-vk2735-phase-2-venture` (already exists, but wait, the slug in our prior notes is `viking-therapeutics-oral-vk2735-phase-2-venture`). Let's check the title: "Viking Therapeutics Advances VANQUISH Phase 3, Sets Q4 2026 Oral Phase 3 Start, and Expands Franchise with Amylin Agonist". Wait, has Viking's status progressed? Yes! The VANQUISH Phase 3 studies (VANQUISH-1 and VANQUISH-2) for subcutaneous VK2735 are now *fully enrolled* and progressing, with primary efficacy data expected in 2027. Also, the highly anticipated Phase 1 maintenance dosing study of VK2735 (which doses obese volunteers with weekly SC VK2735 for 19 weeks, then switches them to monthly SC, daily/weekly oral, or placebo) is guided to read out in Q3 2026. This is considered an underappreciated catalyst that could re-rate the stock, as it addresses a key commercial weakness of GLP-1s (weight regain and discontinuation) by testing flexible, less-frequent maintenance dosing. Viking's financial position (as of June 30, 2026): TTM Revenue $0, Q2 Operating Loss $132.6M, Cash $125.8M. Market Cap is $3.75B. Let's update `viking-therapeutics-oral-vk2735-phase-2-venture` or write a note about Viking's pipeline. Let's see if we should update `viking-therapeutics-oral-vk2735-phase-2-venture`. Let's do that! What about Structure Therapeutics? `structure-therapeutics-aleniglipron-access-ii-results` - "Structure Therapeutics Doses First Patients in Phase 3 ACCOMPLISH Program, Bolstered by $1.3B Cash Runway". Wait! Let's check Structure's latest financial results: As of June 30, 2026: TTM Revenue $0, Q2 Operating Loss $118.6M, Cash $272.6M, Total Debt $6.2M. Market Cap is $3.38B. And aleniglipron is progressing to Phase 3 trials (ACCOMPLISH program) following Phase 2b results showing up to 16.2% weight loss. Wait, let's look at whether we need to update this note or create a new one. Let's update `structure-therapeutics-aleniglipron-access-ii-results` to reflect the latest Q2 2026 financial status and pipeline progression. What about Kailera Therapeutics? We have: `oral-glp1-patent-litigation-kailera-structure` - "Kailera Targets Structure's '183 Patent in European Dispute, Escalating Section 1782 Discovery Case". Let's see what's happening with Kailera: Kailera (KLRA) is a major new player that completed a massive IPO in April 2026 but has since seen its stock fall ~28.8% to a new 52-week low of $16.21 (market cap $2.10B). Kailera's lead asset is ribupatide (KAI-9531), a GLP-1/GIP dual agonist licensed from Jiangsu Hengrui Pharmaceuticals (ex-Greater China rights). The global Phase 3 KaiNETIC program of 4,700+ participants is active, and US Phase 2b high-dose data is expected mid-2027. Kailera's financial status as of June 30, 2026: TTM Revenue $0, Q2 Net Loss $111.3M, Cash $130.3M. Wait, the 247wallst article says they have a $1.17 billion cash runway into mid-2028? Ah, let's check: "Kailera holds $1.17 billion in cash and marketable securities, posted a Q2 net loss of $111.31 million, and has runway into mid-2028." But our `market_view` says: "the company holds $130.3 million in cash against $10.2 million in total debt." Wait, maybe the rest is in marketable securities or short-term investments that are not counted as pure cash in the basic cash field but are part of current assets (which shows a current ratio of 11.11, so they have plenty of current assets). Let's be precise and quote both or mention their massive cash/marketable securities reserve. And Kailera is considered a highly attractive acquisition target for players like Pfizer, AstraZeneca, Merck, or AbbVie looking for ex-China rights to a Phase 3-ready GLP-1/GIP dual agonist. Meanwhile, the legal dispute with Structure Therapeutics continues, with the ex parte application for Section 1782 discovery assistance filed in July 2026 still pending in the Northern District of California before Judge Thomas S. Hixson. Let's update `oral-glp1-patent-litigation-kailera-structure` to incorporate these critical clinical, financial, and strategic updates for Kailera. Let's write these notes! First, let's write/update the note for `eli-lilly-foundayo-orforglipron-fda-approval`. Let's draft it. Wait, let's make sure we have all the rules: - Carry 1-2 representative verbatim quotes, copied exactly, each kept with the link it came from. - Say what it means. - Name and link the actual thing. - No YAML frontmatter. First heading is `# Title`. - Link other findings using `[[slug]]` syntax. - Ground everything in what we consulted this cycle. Let's write `eli-lilly-foundayo-orforglipron-fda-approval`: Title: Eli Lilly's Foundayo and Novo Nordisk's Wegovy Pill Clash in Oral GLP-1 Showdown Let's do this first.

I will now write the updated finding for Eli Lilly's oral GLP-1 drug Foundayo (orforglipron) and its competitive clash with Novo Nordisk's Wegovy pill, incorporating the latest financial data and market dynamics.

I will now update the note for Viking Therapeutics, incorporating the latest clinical trial enrollment updates, the anticipated Q3 2026 Phase 1 maintenance study readout, and their Q2 2026 financial profile.

I will now update the note for Structure Therapeutics to reflect aleniglipron's Phase 3 program progression and the company's Q2 2026 financial performance.

I will now update the note for Kailera Therapeutics, reflecting its post-IPO market trajectory, pipeline developments for ribupatide, and its ongoing legal battle with Structure Therapeutics.

I have written and updated all relevant findings. I will now call `finish_cycle` to complete this research cycle.

I have successfully completed the research cycle for topic **019e84f3-e46c-7c64-bcce-6d0ef82f7c3f**. Here is a summary of the key findings and updates recorded during this cycle: 1. **Eli Lilly's Foundayo and Novo Nordisk's Wegovy Pill Clash in Oral GLP-1 Showdown (`eli-lilly-foundayo-orforglipron-fda-approval`)** * **FDA Approval & Launch:** Lilly's oral obesity pill **Foundayo™ (orforglipron)** was approved on April 1, 2026, under the expedited FDA Commissioner's National Priority Voucher (CNPV) pilot program in just 50 days (nearly 10 months ahead of its original PDUFA date). * **Clinical Edge:** Unlike Novo Nordisk's Wegovy pill, Foundayo has no food or water restrictions. * **Pricing & Access:** Launched via LillyDirect starting at $25/month with commercial coverage and $149/month for self-pay. It is also integrated into the Medicare GLP-1 Bridge program for a $50/month copay. * **Financial Divergence:** Lilly's TTM revenue reached $79.67B (+47.7% YoY) with a 54.2% operating margin, while Novo Nordisk's TTM revenue stood at $329.43B (+2.1% YoY) with a 42.5% operating margin. 2. **Viking Therapeutics Advances VANQUISH Phase 3 and Maintenance Dosing Timeline (`viking-therapeutics-oral-vk2735-phase-2-venture`)** * **Phase 3 VANQUISH Program:** Both VANQUISH-1 and VANQUISH-2 trials for weekly subcutaneous VK2735 are now fully enrolled, with primary data expected in 2027. * **Near-Term Catalyst:** The highly anticipated Phase 1 exploratory maintenance dosing trial of VK2735 is scheduled to read out in **Q3 2026** (by September 30), evaluating the transition of patients to monthly subcutaneous dosing or oral formulations to prevent weight regain. * **Financial Profile:** Reported $0 TTM revenue, a Q2 operating loss of $132.6M, and holds $125.8M in cash. 3. **Structure Therapeutics Phase 3 ACCOMPLISH Progress (`structure-therapeutics-aleniglipron-access-ii-results`)** * **Phase 3 Dosing:** Dosed the first patients in its Phase 3 **ACCOMPLISH** program for oral aleniglipron (GPCR-183) on August 6, 2026, following strong Phase 2b data showing 16.2% weight loss. * **Upcoming Q4 Readouts:** Topline readouts for a 44-week Body Composition study and a 12-week SWITCH trial (transitioning from injectable GLP-1s to oral aleniglipron) are set for Q4 2026. * **Financial Profile:** Reported a Q2 operating loss of $118.6M and holds $272.6M in cash (with over $1.3B in broader runway). 4. **Kailera Therapeutics' Post-IPO Path and Legal Dispute (`oral-glp1-patent-litigation-kailera-structure`)** * **Market Trajectory:** Kailera (KLRA) stock has declined 28.8% since its April IPO, hitting a new 52-week low of $16.21 (market cap of $2.10B). * **Ribupatide Pipeline:** Ribupatide (KAI-9531) is active in the global Phase 3 KaiNETIC program (4,700+ participants). High-dose Phase 2b data is expected mid-2027, and oral Phase 3 trials are set for H1 2027. * **Legal Battle:** Kailera's Section 1782 ex parte application (Case No. 3:2026mc80216) to compel Structure and Gasherbrum Bio to hand over documents for its European patent challenge remains pending before Judge Thomas S. Hixson in the Northern District of California.